Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04427709 · ClinicalTrials.gov registry record · Phase 2
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
A Phase 2 study of Chronic Pain and Osteoarthritis, Knee, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04427709: Recruiting Phase 2 study of Chronic Pain and Osteoarthritis, Knee, sponsored by Wake Forest University Health Sciences.
NCT04427709 is a Phase 2 study of Chronic Pain and Osteoarthritis, Knee that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 38 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04427709, a Phase 2 study of Chronic Pain and Osteoarthritis, Knee, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate the effects of oxytocin (naturally occurring hormone) given by an intramuscular (IM; into the muscle) injection, has on your parasympathetic nervous system. The parasympathetic nervous system is the part of the involuntary nervous system that is sometimes called the "rest and digest" system; the parasympathetic system conserves energy as it slightly slows the heart rate, increases intestinal and gland activity, and relaxes sphincter muscles in the gastrointestinal tract.
Primary Outcome
Magnitude of power at the dominant frequency in the Fourier transform of pupil diameter. One measure of coefficient of variation at each time period. It is calculated by the amount of variability in a window of time. Every 2.5 minutes beginning 20 minutes before the intramuscular injection of placebo or oxytocin, 25 micrograms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT04427709 shows while recruiting
NCT04427709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04427709 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04427709 about?
NCT04427709 is a clinical study titled "Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity". The purpose of this research is to evaluate the effects of oxytocin (naturally occurring hormone) given by an intramuscular (IM; into the muscle) injection, has on your parasympathetic nervous system. The parasympathetic nervous system is the part of the involuntary nervous system that is sometimes ...
What is the current status of trial NCT04427709?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-11-30. Estimated completion is 2026-12.
What conditions does trial NCT04427709 study?
This clinical trial studies the following conditions: Chronic Pain, Osteoarthritis, Knee.
What interventions are being tested in trial NCT04427709?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT04427709?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04427709 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04427709's enrollment target sits among peer trials
38 224th of 301 higher than 76 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
-
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI